Japanese Journal of Clinical Oncology, Vol 29, Issue 2 92-95, Copyright © 1999 by Foundation for Promotion of Cancer Research
A Ozkan, I Yildiz, L Yuksel, H Apak and T Celkan
BACKGROUND: We aimed to assess the potency and efficacy of tropisetron, a
5-HT3 receptor antagonist, in the prevention of nausea and emesis observed
in the pediatric patient population taking various chemotherapy protocols.
METHODS: Tropisetron (Navoban) was given to 100 children (62 boys and 38
girls aged 6 months to 15 years) with various malignancies. Patients
received tropisetron during one or more courses of emetogenic chemotherapy
for a total of 350 courses administered intravenously or intravenously and
intrathecally. Tropisetron (0.2 mg/kg/day, maximum: 5 mg/day) was
administered as a single intravenous dose slowly, before the start of
chemotherapy on day 1 and intravenously or by mouth on subsequent days
(median treatment duration: 5 days). RESULTS: The patients receiving
cytotoxic chemotherapy had a 70% complete response rate and a 24% partial
response rate during the first 24 h period of the first course. We observed
headache (five courses), diarrhea (three courses) and loss of appetite (one
course) as side-effects (2.5%). CONCLUSION: Tropisetron is safe, effective,
easy to use, has no serious side-effects and can be recommended for
pediatric patients. The efficacy of tropisetron may be enhanced by the
addition of corticosteroids in patients receiving highly emetogenic cancer
chemotherapy.
CASE REPORTS
Tropisetron (Navoban) in the control of nausea and vomiting induced by combined cancer chemotherapy in children
Cerrahpasa Medical Faculty, Department of Pediatric Hematology-Oncology, University of Istanbul, Turkey.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Hockenberry Symptom Management Research in Children With Cancer Journal of Pediatric Oncology Nursing, May 1, 2004; 21(3): 132 - 136. [Abstract] [PDF]
|
|